Physician profile
Thomas A Rossi
NPI 1821083528
$4,293.05
in general payments reported to CMS, 2019-2025
27 companies · $735 in 2025
The $735 reported for 2025 was more than what 89% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $495 · 2021: $540 · 2022: $999 · 2023: $735 · 2024: $310 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,304.59 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $955.65 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $343.51 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $284.29 | 2022 | |
| Almatica Pharma LLC | $268.22 | 2022-2023 | Gralise |
| Ipsen Biopharmaceuticals, INC | $156.15 | 2020-2025 | Dysport |
| Biohaven Pharmaceuticals, INC. | $115.68 | 2021 | |
| Amgen INC. | $104.28 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $103.65 | 2025 | |
| Arbor Pharmaceuticals, INC. | $102.58 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $99.08 | 2021-2022 | |
| Abbott Laboratories | $80.32 | 2022-2025 | Eterna, Proclaim |
| Alfasigma USA, INC. | $50.73 | 2021-2022 | |
| Bioventus LLC | $46.64 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $35.65 | 2025 | Xeomin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.11 | 2020-2021 | |
| Lilly USA, LLC | $34.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.35 | 2022-2023 | Relistor |
| Saluda Medical Americas, INC. | $29.50 | 2025 | Evoke |
| Endo USA, INC. | $16.55 | 2025 | Xiaflex |
| Scilex Pharmaceuticals INC. | $14.91 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.74 | 2019 | |
| Assertio Therapeutics, INC. | $13.33 | 2019 | |
| Depuy Synthes Sales INC. | $13.31 | 2024 | Orthovisc, Monovisc |
| Ferring Pharmaceuticals INC. | $12.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2019 | |
| Allergan, INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.